Physician profile
Salman S Butt
NPI 1760664585
$461.36
in general payments reported to CMS, 2019-2025
15 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.83 · 2020: $65.84 · 2021: $30.96 · 2022: $28.26 · 2023: $159 · 2024: $40.97 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $96.37 | 2022-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $57.30 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $50.26 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.62 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $30.07 | 2023-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $29.18 | 2025 | Acthar |
| Lilly USA, LLC | $20.90 | 2024 | Jardiance |
| Novo Nordisk INC | $20.20 | 2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $19.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.55 | 2023 | |
| Boston Scientific Corporation | $17.67 | 2023 | Varithena Administration Pack |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Butt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.